Coldstream Capital Management’s Integra LifeSciences IART Stock Holding History

Coldstream Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,332	Closed	-$97.3K	–	1262
2026 Q1	$97.3K	Buy	+10,332	New	+$113K	﹤0.01%	1161
2025 Q2	–	Sell	-5,474	Closed	-$120K	–	2122
2025 Q1	$120K	Buy	+5,474	New	+$129K	﹤0.01%	1256
2019 Q4	–	Sell	-3,329	Closed	-$200K	–	359
2019 Q3	$200K	Buy	+3,329	New	+$198K	0.02%	322
2018 Q4	–	Sell	-3,957	Closed	-$261K	–	348
2018 Q3	$261K	Buy	3,957 +112	+3%	+$6.96K	0.02%	286
2018 Q2	$248K	Buy	3,845 +105	+3%	+$6.5K	0.03%	274
2018 Q1	$207K	Buy	+3,740	New	+$196K	0.02%	277
2017 Q3	–	Sell	-3,745	Closed	-$204K	–	310
2017 Q2	$204K	Buy	+3,745	New	+$179K	0.03%	264

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Coldstream Capital Management's IART Position: Q2 2026 in Review

Coldstream Capital Management sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 10,332 shares — an estimated $97.3K sold.

Coldstream Capital Management first reported a position in IART in Q2 2017 and held it in 7 quarters. The position peaked at $261K in Q3 2018. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Coldstream Capital Management reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
Coldstream Capital Management sold 10,332 Integra LifeSciences shares in Q2 2026, an estimated $97.3K.
Coldstream Capital Management first reported a position in Integra LifeSciences in Q2 2017 and held it in 7 quarters.
Coldstream Capital Management's Integra LifeSciences position peaked at $261K in Q3 2018.
213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.